Neural Implants and Stimulation
Stimulation - not recording - has produced the largest and most durable clinical wins of the neurotechnology era. Deep brain, spinal cord, vagus, sacral, and cochlear stimulators have collectively been implanted in more than 1.5 million people, with closed-loop systems that adapt in real time now the dominant frontier.
Key facts
- DBS is FDA-approved for at least 5 conditions and has been implanted in over 200,000 patients globally.
- More than 1 million cochlear implant recipients globally (NIDCD, 2024).
- Targeted epidural stimulation has restored independent walking in motor-complete spinal cord injury (Nature Medicine 2022; Lancet Neurology 2024).
- Closed-loop DBS (Medtronic Percept) became broadly clinically available in 2020-2023.
- Onward ARC-EX received FDA De Novo authorisation in 2024 for SCI rehabilitation.
- Focused ultrasound thalamotomy has been FDA-approved for essential tremor since 2016.
- NeuroPace RNS has been FDA-approved for drug-resistant focal epilepsy since 2013.
Deep Brain Stimulation
Deep brain stimulation (DBS) delivers electrical pulses to subcortical targets via stereotactically placed leads connected to an implanted pulse generator (IPG). It is FDA-approved for Parkinson's disease (1997, 2002), essential tremor (1997), dystonia (Humanitarian Device Exemption, 2003), OCD (HDE, 2009), and drug-resistant epilepsy (RNS, 2013). More than 200,000 patients have received DBS implants globally as of 2024.
Closed-loop, sensing-enabled systems - Medtronic Percept PC and Percept RC, Abbott Liberta RC - record local field potentials and adjust stimulation parameters in response to disease-state biomarkers such as beta oscillations in Parkinson's. The NeuroPace RNS System for epilepsy detects seizure onsets and delivers targeted stimulation to abort them.
- Typical Parkinson's STN-DBS reduces medication dose by ~50% and ON-time without dyskinesia by 4-5 hours per day.
- Essential-tremor VIM-DBS delivers 60-90% tremor reduction in responders.
- Battery life: 3-5 years for non-rechargeable IPGs, 10-15+ years for rechargeable units.
- Adverse events include hemorrhage (~1-2%), infection (~3-5%), hardware failure, and stimulation-related side effects.
Spinal Cord Stimulation
Conventional spinal cord stimulation (SCS) is the highest-volume neuromodulation therapy worldwide, primarily indicated for failed back surgery syndrome and complex regional pain syndrome. Newer high-frequency (Nevro Senza, 10 kHz), burst (Abbott BurstDR), and differential-target multiplexed paradigms have improved analgesia profiles and reduced paresthesia compared with traditional tonic stimulation.
Targeted epidural stimulation (EPFL/CHUV STIMO program, Onward ARC-IM) has restored independent overground walking in people with motor-complete spinal cord injury - results published in Nature Medicine (2022, Rowald et al.) and Lancet Neurology (2024). Onward ARC-EX received FDA De Novo authorisation in 2024 as the first non-invasive spinal stimulator cleared for SCI rehabilitation.
Psychiatric and Cognitive Indications
DBS for treatment-resistant depression has been studied in multiple targets including subcallosal cingulate (SCC, Mayberg), ventral capsule/ventral striatum (VC/VS), medial forebrain bundle, and lateral habenula. Multi-centre RCTs have produced mixed results; personalised closed-loop work (Scangos et al., Nature Medicine 2021) demonstrated dramatic sustained response in a single patient using individualised stimulation biomarkers.
Focused ultrasound (Insightec Exablate) offers incisionless thermal ablation for essential tremor (FDA, 2016) and Parkinsonian tremor, with active trials in OCD and treatment-resistant depression.
Vagus nerve stimulation is FDA-approved for treatment-resistant depression (2005) and epilepsy; SetPoint Medical's closed-loop bioelectronic system is in pivotal trials for rheumatoid arthritis.
Sensory Restoration
Cochlear implants are the most successful neural prosthesis in history with more than 1 million recipients worldwide (NIDCD, 2024). Modern devices deliver 22 channels of cochlear stimulation and routinely restore open-set speech understanding in quiet.
Retinal implants have had a more difficult trajectory. The Argus II (Second Sight) was discontinued in 2019 and the company entered bankruptcy in 2020; PRIMA (Pixium / Science Corporation) is in trials for advanced atrophic age-related macular degeneration.
Auditory brainstem implants serve patients ineligible for cochlear implants (e.g., bilateral cochlear-nerve absence). Vestibular implants are in early human trials for chronic bilateral vestibular hypofunction (Johns Hopkins, MED-EL).
Closed-Loop and Adaptive Stimulation
Adaptive stimulation systems that sense neural biomarkers and modulate output in real time are now the standard direction across DBS, SCS, and epilepsy stimulation. Medtronic Percept PC and BrainSense, Abbott NeuroSphere, and NeuroPace RNS are the most clinically established adaptive platforms.
Machine-learning controllers trained on multi-day intracranial recordings are an active research direction, with personalised closed-loop DBS for depression and OCD being the most prominent clinical demonstrations to date.
Frequently asked
Is DBS dangerous?
+
DBS carries the standard risks of stereotactic neurosurgery: hemorrhage at roughly 1-2%, infection at 3-5%, and hardware-related complications. For appropriately selected patients with otherwise refractory disease, it is well tolerated and frequently life-changing. It is not appropriate for every patient; comprehensive multidisciplinary evaluation is the standard of care.
Can stimulation cure depression?
+
Stimulation does not cure depression, but it can produce durable response in treatment-resistant cases. Vagus nerve stimulation has FDA approval for TRD (2005). DBS for TRD remains investigational; personalised closed-loop approaches show promise but large definitive RCT evidence is still maturing. Repetitive transcranial magnetic stimulation (rTMS) is the only FDA-cleared brain-stimulation therapy for major depressive disorder, and is widely used clinically.
How long do stimulators last?
+
Rechargeable implanted pulse generators typically last 10 to 15 years before requiring replacement. Non-rechargeable batteries last 3 to 7 years depending on stimulation parameters. Lead replacement is rarer but does occur over a patient's lifetime. Routine planning for revision surgery is part of long-term DBS, SCS, and VNS care.
What is the difference between DBS and TMS?
+
Deep brain stimulation is invasive: surgically implanted electrodes deliver continuous or closed-loop stimulation to specific deep brain targets. Transcranial magnetic stimulation is non-invasive: an external coil generates a magnetic field that induces neural activity in the cortex. DBS is for severe, refractory conditions; TMS is widely used for depression and OCD.
Does insurance cover neural stimulators?
+
In the US, Medicare and most major commercial payers cover FDA-approved indications: DBS for Parkinson's, essential tremor, and dystonia; SCS for FBSS and CRPS; cochlear implants; VNS for refractory epilepsy and TRD; and RNS for drug-resistant focal epilepsy. Coverage for off-label or HDE indications is more variable.
Sources & further reading
Continue in this series
Foundations
Brain-Computer Interfaces: An Overview
Industry
Neuralink, Synchron, and the BCI Industry
Frontier
Memory Prosthetics and Cognitive Augmentation
Ethics
Neurorights and the Ethics of Reading the Brain
Outlook
The Future of Brain-Computer Interfaces